Breast cancer (BC) is one of the most common causes of cancer deaths worldwide [1]. Neoadjuvant chemotherapy (NAC) is increasingly used in patients with locally advanced BC and early-stage BC, aiming at reducing the tumor burden and thus improving eligibility for breast-conserving surgery. The pathological complete response (pCR) after NAC is considered a strong prognostic factor, as previous studies demonstrated that patients exhibiting pCR present better long-term outcomes than those without p…